Furestem-ra inj (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 3 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03618784 (ClinicalTrials.gov) | July 11, 2018 | 24/7/2018 | Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis | A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase I/2a Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. for Moderate to Severe Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: FURESTEM-RA Inj;Other: sterile saline | Kang Stem Biotech Co., Ltd. | NULL | Recruiting | 19 Years | 80 Years | All | 33 | Phase 1;Phase 2 | Korea, Republic of |
| 2 | NCT03106259 (ClinicalTrials.gov) | June 29, 2016 | 3/4/2017 | Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj | Observational Study to Evaluate the Safety of FURESTEM-RA Inj. in Moderate to Severe Rheumatoid Arthritis Patients Who Participated in Phase 1 Clinical Trial of FURESTEM-RA Inj | Rheumatoid Arthritis | Drug: FURESTEM-RA Inj. | Kang Stem Biotech Co., Ltd. | NULL | Active, not recruiting | 19 Years | 80 Years | All | 9 | Phase 1 | Korea, Republic of |
| 3 | NCT02221258 (ClinicalTrials.gov) | October 2014 | 18/8/2014 | Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA) | Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: FURESTEM-RA Inj. | Kang Stem Biotech Co., Ltd. | NULL | Completed | 19 Years | 80 Years | Both | 9 | Phase 1 | Korea, Republic of |